logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Melinta Therapeutics, LLC drugs

    FiltersReset Filters
    7 results

    • baxdela

      (delafloxacin meglumine)
      Melinta Therapeutics, LLC
      Usage: BAXDELA is indicated for adults with acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia caused by specific susceptible microorganisms, including MRSA and various strains of Streptococcus and Enterobacter. It should be used to mitigate drug-resistant bacteria development.

    • kimyrsa

      (oritavancin diphosphate)
      Melinta Therapeutics, LLC
      Usage: KIMYRSA® is indicated for treating adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by specific Gram-positive bacteria, including methicillin-susceptible and resistant Staphylococcus aureus, various Streptococcus species, and vancomycin-susceptible Enterococcus faecalis. Use only for proven or suspected susceptible infections.

    • minocin - minocycline hydrochloride injection

      (Minocycline Hydrochloride)
      Melinta Therapeutics, Llc

    • orbactiv

      (oritavancin)
      Melinta Therapeutics, LLC
      Usage: ORBACTIV® (oritavancin) is indicated for treating adult patients with acute bacterial skin and skin structure infections caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus and vancomycin-susceptible Enterococcus faecalis. It should be used to prevent drug-resistant bacteria and tailored based on culture results when available.

    • rezzayo

      (rezafungin)
      Melinta Therapeutics, LLC
      Usage: REZZAYO is indicated for adults with limited or no alternative treatment options for candidemia and invasive candidiasis. It has not been studied for conditions such as endocarditis, osteomyelitis, or meningitis caused by Candida. Initiating therapy prior to laboratory results is allowed, with adjustments as needed after results.

    • toprol xl - metoprolol succinate tablet, extended release

      (Metoprolol Succinate)
      Melinta Therapeutics, Llc

    • vabomere

      (Meropenem-Vaborbactam)
      Melinta Therapeutics, LLC
      Usage: VABOMERE® is indicated for treating complicated urinary tract infections (cUTI), including pyelonephritis, in patients 18 and older, caused by susceptible bacteria such as E. coli, Klebsiella pneumoniae, and Enterobacter cloacae species complex. It aims to reduce drug-resistant bacteria development.